Can a One-Year bone drug switch beat standard therapy for Steroid-Induced bone loss?
NCT ID NCT07757373
First seen Aug 11, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This study follows people with bone loss caused by long-term steroid use to compare two treatment approaches. One group received romosozumab for the first year and then switched to denosumab, while the other group took denosumab throughout. After six years, researchers will measure bone mineral density to see which strategy better preserves bone strength.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Romosozumab followed by denosumab, compared with denosumab alone
- What this could lead to
- If successful, this could show which treatment sequence better preserves bone density over the long term for people on chronic steroids, potentially guiding safer osteoporosis care.
- What could go wrong
- This is a small, extended observation of an earlier trial, not a fresh large study. Results may not apply broadly, and bone density changes do not guarantee fewer fractures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 54 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: \- patients who are continued on 6-monthly subcutaneous injection of DEN in either the ROMO or DEN arms after month 48; (2) those who are willing to have a repeat DXA assessment at the end of 6 years Exclusion Criteria: * patients who refuse to be maintained on denosumab after month 48 * patients who are maintained on other anti-osteoporotic drugs after month 48 * patients in whom prednisolone is planned to be tapered or discontinued after month 48.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Glucocorticoid-associated osteopenia and osteoporosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Tuen Mun Hospital
Hong Kong, Hong Kong